You are here


Human Single Domain Antibodies Targeting CD16A to Mediate ADCC

Researchers at the National Cancer Institute (NCI) have developed fully human, single-domain antibodies targeting CD16A for engaging antibody dependent cellular cytotoxicity (ADCC). The invention antibodies have been used in bispecific killer cell engagers (BiKEs) for targeting HIV-1. The BiKEs have been tested in vitro and in vivo with promising results. The single domain antibodies have potential therapeutic uses in a variety of indications due to their ability to engage ADCC.
NIH Reference Number
Product Type
  • single domain antibody, CD16A, HIV-1, antibody dependent cellular cytotoxicity (ADCC), bispecific killer cell engagers (BiKEs)
Collaboration Opportunity
This invention is available for licensing and co-development.
Description of Technology

Natural killer cells are coated with Fc receptors and can be activated through the binding of antibodies to these Fc receptors. Once activated, natural killer cells engage in antibody dependent cellular cytotoxicity (ADCC), wherein a target cell is lysed by the natural killer cells, causing the target cell to secrete cytokines that recruit adaptive immune cells.

Researchers at the National Cancer Institute (NCI) developed fully human single domain antibodies targeting CD16A, a Fc receptor found on the surface of natural killer cells. The invention antibodies have high binding affinity and specificity to CD16A. Researchers have incorporated the invention antibodies in bispecific killer cell engagers (BiKEs) for targeting HIV-1.  However, these single domain antibodies could also be used in the treatment of a variety of other diseases, including cancer.  

Potential Commercial Applications

• Antibody-based therapeutic for treatment of cancer 
• Antibody-based therapeutic against HIV-1

Competitive Advantages

• Fully human antibodies are likely to have less toxicity associated with them and thus, an improved drug safety profile
• Potential use in a variety of therapeutic applications where ADCC is a necessary component of treatment
• BiKEs could overcome self-inhibitory signals
• Relevance to a wide range of cancers


Dimiter Dimitrov (NCI), Wei Li (NCI), Weizao Chen (NCI)

Development Stage
Patent Status
  • U.S. Provisional: U.S. Provisional Patent Application Number 62/379,582, Filed 25 Aug 2016
Therapeutic Area
Friday, October 27, 2017